Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.34 |
| ▸ | POLQ | O75417 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | ACP3 | P15309 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | MC4R | P32245 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10796149 | 0.77 | P2RX7 (0.50) | P2RX7IDO1SLC6A2HSD11B1ACP3 | |
| SCHEMBL84477 | 0.75 | P2RX7 (0.50) | P2RX7IDO1SLC6A2HSD11B1ACP3 | |
| SCHEMBL28416045 | 0.74 | P2RX7 (0.41) | P2RX7IDO1SLC6A4SLC6A2POLQ | |
| SCHEMBL21483795 | 0.73 | — | — | |
| SCHEMBL20801062 | 0.72 | POLQ (0.37) | SLC6A4POLQCNR2 | |
| SCHEMBL30270585 | 0.72 | TSHR (0.53) | P2RX7IDO1SLC6A4HSD11B1ACP3 | |
| SCHEMBL10120401 | 0.72 | TSHR (0.53) | P2RX7IDO1SLC6A4HSD11B1ACP3 | |
| SCHEMBL18629857 | 0.72 | RECQL (0.33) | SLC6A2 | |
| SCHEMBL807279 | 0.71 | P2RX7 (0.48) | P2RX7IDO1SLC6A2HSD11B1TRPA1 | |
| SCHEMBL13662506 | 0.70 | P2RX7 (0.44) | P2RX7IDO1SLC6A4SLC6A2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174228-B2 | Antagonists of human integrin (α4)(β7) | MORPHIC THERAPEUTIC, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20200385352-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2020-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174228-B2 | Antagonists of human integrin (α4)(β7) | ITGB7, ITGB4, ITGA4 | P2RX7 112/4885IDO1 4684/4885SLC6A4 2951/4885 |
| US-20200385352-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | ITGB7, ITGB4, ITGA4 | P2RX7 129/4885IDO1 4597/4885SLC6A4 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.